secwatch.observer — SEC 8-K summary
======================================

Issuer:     InfuSystem Holdings, Inc (INFU)
CIK:        0001337013
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001628280-24-045952
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

InfuSystem reports record Q3 revenue of $35.3M, up 11% YoY; net income +162%
----------------------------------------------------------------------------

- Net revenue $35.3M (+11% YoY); Patient Services $20.8M (+8%), Device Solutions $14.5M (+15%).
- Net income $1.8M (+162%), diluted EPS $0.08; Adj EBITDA $7.9M (+27%), margin 22.3%.
- Operating cash flow YTD $12.5M (+91%); liquidity $46.9M as of Sept 30, 2024.
- Reaffirms FY2024 guidance: high-single-digit revenue growth, Adj EBITDA margin high-teens.
- New partnerships: Smith+Nephew for NPWT and exclusive Chemo Mouthpiece deal with Sanara MedTech.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1337013/000162828024045952/0001628280-24-045952-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1337013/000162828024045952/infu-20241107.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-045952

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer